The AMA, perhaps turning the tables on the health insurance industry's push toward doctor ratings, has begun its first ever health insurer report card. Dr. William Dolan, AMA board member, tells Bruce Japsen about how the AMA rates certain business practices of health plans that slow payments to doctors and confuse consumers. The AMA calls the effort the "Cure for Claims," which rates major national insurers. For more information, refer to the following AMA website link: ama-assn.org/go/cureforclaims.
A Treatment for Medical Claims: The First Health Insurer Report Card
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
The AMA, perhaps turning the tables on the health insurance industry's push toward doctor ratings, has begun its first ever health insurer report card. Dr. William Dolan, AMA board member, tells Bruce Japsen about how the AMA rates certain business practices of health plans that slow payments to doctors and confuse consumers. The AMA calls the effort the "Cure for Claims," which rates major national insurers. For more information, refer to the following AMA website link: ama-assn.org/go/cureforclaims.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
CME/CE
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
0.50 credits
<p>Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
Clinician's Roundtable
AI and Hair Loss: Measuring Progress with Data-Driven Insights
<p>AI and Hair Loss: Measuring Progress with Data-Driven Insights</p>
Clinician's Roundtable
Challenges in AI-Driven Dermatology: Understanding Current Limitations
<p>Challenges in AI-Driven Dermatology: Understanding Current Limitations</p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?